Fig 1: MSC-exo and Dt-MSC-exo Promote the Expression of S100A6 in BCs by Delivering miR-21-5p(A and B) Relative expression of miR-21-5p in MSCs (A) and MSC-exo (B). The Dox-treated group displayed a higher content than did the control group. (C and D) MDA-MB-231 cells and MCF-7 cells were transfected with miR-21-5p antagomir or negative control scrambled RNA. Relative expression of miR-21-5p (C) and S100A6 (D) in MDA-MB-231 cells (left) and MCF-7 cells (right) treated with miR-21-5p antagomir. Two independent experiments showed similar results. (E and F) Reduced miR-21-5p expression in MSCs (E) and MSC-exo (F). (G) The mRNA and protein expression of S100A6 in MSC-exo and Dt-MSC-exo measured after treatment with miR-21-5p antagomir. Two independent experiments showed similar results. The data are mean ± SD, averaged from three separate experiments. *p < 0.05, **p < 0.01. n.s., not significant.
Fig 2: The effects of isoflurane anesthesia and surgery on the common altered proteins in aged rats. (A) Representative immunoblots illustrating the common affected proteins in the hippocampus after surgery. (B) Sevoflurane anesthesia plus surgery reduced 14-3-3ß/a and increased haptoglobin, S100A6, and biliverdin reductase-A expression levels in the hippocampus. (C) Representative immunoblots illustrating the common altered proteins in the prefrontal cortex after surgery. (D) Sevoflurane anesthesia plus surgery reduced 14-3-3ß/a and increased haptoglobin and S100A6 expression levels in the prefrontal cortex. (E) Representative immunoblots illustrating the common altered proteins in the temporal lobe after surgery. (F) Sevoflurane anesthesia plus surgery decreased 14-3-3ß/a and increased haptoglobin and a-2 macroglobulin expression levels in the temporal lobe. Values are expressed as the mean ± SEM (n = 5 per group). *p < 0.05, **p < 0.01, and ***p < 0.001 surgery versus control rats.
Fig 3: The expression of six proteins was altered in the hippocampus, prefrontal cortex, and temporal lobe of aged rats by surgery plus isoflurane according to quantitative proteomics analyses. (A) Surgery decreased 14-3-3ß/a and biliverdin reductase-A (BVR-A) levels and increased haptoglobin, caseinolytic protease (ClpP), and a-2 macroglobulin (A2M) levels in the hippocampus. (B) Surgery reduced 14-3-3ß/a and BVR-A levels and increased haptoglobin, S100A6, ClpP, and A2M levels in the prefrontal cortex. (C) Surgery decreased 14-3-3ß/a, S100A6, and BVR-A levels and increased haptoglobin, ClpP, and A2M levels in the temporal lobe. The results ae presented as the mean ± SEM (n = 9 per group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 surgery vs. control group.
Fig 4: Screening for Genes Affected by Exosomes Secreted by Dox-Pretreated MSCs and Identifying the Increase of S100A6 Expression in BCs(A and B) Differentially expressed proliferation-related genes in untreated MCF-7 cells and MSC-exo-treated MCF-7 cells are displayed in a volcano plot (A) and heatmap (B). Quantitative PCR analysis of exosome-treated BCs. (C and D) MCF-7 (C) and MDA-MB-231 (D) cells treated with MSC-exo and Dt-MSC-exo. The relative levels of S100A6, FOSB, ARHGDIB, SOD3, and ApoD in the Cont, MSC-exo, and Dt-MSC-Exo. (E) Western blot analysis. Images are representative of three independent experiments. Data are expressed as the mean ± SD of the relative values from three independent experiments. *p < 0.05, **p < 0.01.
Fig 5: Downregulation of S100A6 in MSCs Has No Significant Effect on the Enhancement of S100A6 by MSC-exo and Dt-MSC-exo in BCs(A–C) The mRNA (A and C) and protein (B) expression of S100A6 in MSCs (A and B) and Dox-treated MSCs (C) after treatment with S100A6-siRNA. (D and E) Downregulation of S100A6 in MSCs: relative expression of S100A6 in MSC-exo and Dt-MSC-exo treated with S100A6-siRNA in MDA-MB-231 (D) and MCF-7 (E) cells. The data are mean ± SD, averaged from three separate experiments. *p < 0.05, **p < 0.01. n.s., not significant.
Supplier Page from Abcam for Anti-S100 alpha 6/PRA antibody [EPR13084-69]